Sun Pharma Advanced Research Company (SPARC) has signed a binding Letter of Intent (LoI) with the University of California, San Francisco (UCSF), through the office of OTMA, and Tiller Therapeutics Inc. (Tiller) to license SPARC’s rights in the joint intellectual property (IP) held between SPARC and UCSF for pre-clinical oncology asset along with associated IP. The LoI outlines the key terms of license and rights for development and commercialization by Tiller.

Under the terms of the LoI, SPARC will receive 55% equity stake in Tiller upon execution of LoI. The equity will vest in two tranches; 45% equity will vest upon execution of license agreement and the remaining 10% equity will vest at the earlier of achievement of certain milestones by Tiller or within 6 months of execution of license agreement. Other terms of the license will be outlined in the license agreement.

Sun Pharma Advanced Research Company is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery.


Sun Pharma Adv. Res Share Price

217.55 2.95 (1.37%)
20-Dec-2024 09:41 View Price Chart
Peers
Company Name CMP
Syngene Internation. 850.55
Sagility India 45.55
AGS Transact Tech 71.40
Just Dial 1026.65
Krystal Integrated 764.75
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.